http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200104415-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f67cf07e3fdc9c7d98b1c36039ec12 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate | 2012-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ff19b92f2facd2be08cbd575759806d |
publicationDate | 2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-20200104415-A |
titleOfInvention | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
abstract | The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects on a human patient mediated by administering a CD19xCD3 bispecific antibody to a human patient, the method comprising: the B cell to T cell ratio of the patient. Wherein a ratio of about 1:5 or less indicates a risk of a potential adverse effect on the patient, or the total number of B cells in the patient, wherein less than about 50 B cells per µl of peripheral blood Includes those indicative of the total B cell count at risk of potential adverse effects on the patient. Accordingly, the present invention relates to a method of administering a CD19xCD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or less and/or a total B cell count of less than about 50 B cells per 1 μl of peripheral blood (administration regimen). In this regard, the method comprises the steps of: (a) administering a first dose of said antibody during a first period; And successively (b) administering a second dose of the antibody for a second period, wherein the second dose exceeds the first dose. In some embodiments, a third dose of the antibody is administered during a third period. Such dosing regimens can be applied to a method of treating malignant CD19 positive lymphocytes or ameliorating and/or preventing adverse effects mediated by administration of the bispecific antibody. The invention also relates to the use of a CD19xCD3 bispecific antibody for the preparation of a pharmaceutical composition for use in the method of the invention. Also disclosed is a pharmaceutical package or kit comprising a first dose and a second dose and an optional third dose of the antibody as defined in the method/dosage regimen of the invention. |
priorityDate | 2011-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 347.